Disease · MONDO_0008420

seborrheic keratosis

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. seborrheic keratosis. Diseases, record MONDO_0008420. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0008420

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: seborrheic keratosis; Open Targets
Open Targets ID: MONDO_0008420; Open Targets
Other names: basal cell papilloma, keratosis Seborrheica, keratosis, seborrheic, keratosis, seborrheic, somatic, seborrheic verruca, senile wart; Open Targets
Disease Ontology: DOID:6498; Disease Ontology
MeSH: D017492; MeSH
NCI Thesaurus: C9006; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 2 drugs, from DailyMed and FDA; Open Targets

Drugs2

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
HYDROGEN PEROXIDE	CHEMBL71595	Small molecule	Approval	DailyMed and FDA	9	7	7	Drugs and targets
SIROLIMUS	CHEMBL413	Small molecule	Phase 1/2	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
FKBP1A	Peptidyl-prolyl cis-trans isomerase FKBP1A	1	FK506-binding protein 1A inhibitor	Phase 1/2	https://conductscience.org/library/genes/2280

Source Drugs and targets

Trials8

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02667275	A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis	Phase 3	487	2017-11-13	Seborrheic Keratosis	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT02667236	A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.	Phase 3	450	2017-11-13	Seborrheic Keratosis	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT03148691	A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis	Phase 2	253	2019-05-06	Seborrheic Keratosis	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT02160626	Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis	Phase 2	172	2018-12-07	Seborrheic Keratosis	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT02667288	An Open-Label Safety Study of A-101 Solution	Phase 3	147	2017-11-17	Seborrheic Keratosis	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT02260180	Study of A-101 for the Treatment of Seborrheic Keratosis	Phase 2	119	2018-12-06	Seborrheic Keratosis	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT01986920	Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis	Phase 1/2	35	2018-12-11	Seborrheic Keratosis (SK)	HYDROGEN PEROXIDE	Its record names the disease	ClinicalTrials.gov
NCT03103893	Novel Compositions for Treating or Preventing Dermal Disorders	Phase 1/2	36		Dermal Atrophy	SIROLIMUS	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials8

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
A-101 Solution vs Vehicle Solution: Percent of Lesions Cleared Scale	56 of 244	0 of 243	487	NCT02667275	Trial comparisons
A-101 Solution vs Vehicle Solution: Proportion of Subjects With All Target Lesions Cleared According to Physician Lesion Assessment Scale	19 of 244	0 of 243	487	NCT02667275	Trial comparisons
A-101 Solution vs Vehicle Solution: deaths from any cause	0 of 244	0 of 243	487	NCT02667275	Trial comparisons
A-101 Solution vs Vehicle Solution: serious adverse events	6 of 244	4 of 243	487	NCT02667275	Trial comparisons
A-101 Solution vs Vehicle Solution: Proportion of Subjects With 3 of 4 Target Lesion Clearance	30 of 223	0 of 227	450	NCT02667236	Trial comparisons
A-101 Solution vs Vehicle Solution: deaths from any cause	0 of 223	0 of 227	450	NCT02667236	Trial comparisons
A-101 Solution vs Vehicle Solution: Proportion of Subjects With Target Lesion Clearance as Assessed by the Physician Lesion Assessment	9 of 223	0 of 227	450	NCT02667236	Trial comparisons
A-101 Solution vs Vehicle Solution: serious adverse events	4 of 223	6 of 227	450	NCT02667236	Trial comparisons

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31761958	DERIVED	1	PubMed
30365590	DERIVED	2	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0008420

GET https://conductscience.org/api/diseases/v1/MONDO_0008420/drugs

API reference For AI assistants